Modality
Multispecific
MOA
KIF18Ai
Target
EGFR
Pathway
Proteasome
Prostate CaMCLAngelman
Development Pipeline
Preclinical
Oct 2017
→ Oct 2027
PreclinicalCurrent
NCT06739179
1,800 pts·Prostate Ca
2022-07→2027-10·Active
NCT07387513
1,114 pts·Prostate Ca
2017-10→2025-02·Recruiting
2,914 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-02-241.1y agoInterim· Prostate Ca
2027-10-121.5y awayInterim· Prostate Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Recruit…
Preclinical
Active
Catalysts
Interim
2025-02-24 · 1.1y ago
Prostate Ca
Interim
2027-10-12 · 1.5y away
Prostate Ca
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06739179 | Preclinical | Prostate Ca | Active | 1800 | BodyWt |
| NCT07387513 | Preclinical | Prostate Ca | Recruiting | 1114 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| BMR-8526 | BioMarin | Phase 1/2 | CD38 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| Bemanaritide | Blueprint Medicines | Phase 2 | CD38 | |
| Talafotisoran | Blueprint Medicines | Phase 2/3 | IL-23 |